Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L H Patterson

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Biochemical Pharmacology|September 1, 1990
Doxorubicin-3'-NH-oestrone-17-oxime-ethyl-carbonyl, a doxorubicin-oestrone conjugate that does not redox cycle in rat liver microsomesN G Hartman, L H Patterson, P Workman, et al.
Free Radical Research|September 28, 1999
Free radicals in irradiated drugs: an EPR studyF A Taiwo, L H Patterson, E Jaroszkiewicz, et al.
Biomedical Mass Spectrometry|June 1, 1982
Metabolism of 4-substituted-N-ethyl-N-methylanilines: chromatographic and mass spectrometric identification of N-oxidation metabolic products formed in vitroD A Cowan, L H Patterson, L A Damani, et al.
Biochemical Society Transactions|February 1, 1996
Rationalisation of the C-S lyase activity of aspartate amino transferaseP H Teesdale-Spittle, H J Adcock, L H Patterson, et al.
Biochemical Pharmacology|October 15, 1987
The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitroM A Graham, D R Newell, J Butler, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxidesP J Smith, N J Blunt, R Desnoyers, et al.
The Open Medical Informatics Journal|September 10, 2009
Analysis of Clinical Record Data for Anticoagulation Management within an EHR SystemT Austin, D Kalra, N C Lea, et al.
The Journal of Pharmacy and Pharmacology|April 1, 1986
In-vitro metabolism of lignocaine to its N-oxideL H Patterson, G Hall, B S Nijjar, et al.
International Journal of Radiation Oncology, Biology, Physics|December 9, 1998
Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrugS M Raleigh, E Wanogho, M D Burke, et al.
Anti-Cancer Drug Design|June 2, 2000
Antitumour prodrug development using cytochrome P450 (CYP) mediated activationL H Patterson, S R McKeown, T Robson, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Biochemical Pharmacology|September 1, 1990
Doxorubicin-3'-NH-oestrone-17-oxime-ethyl-carbonyl, a doxorubicin-oestrone conjugate that does not redox cycle in rat liver microsomesN G Hartman, L H Patterson, P Workman, et al.
Free Radical Research|September 28, 1999
Free radicals in irradiated drugs: an EPR studyF A Taiwo, L H Patterson, E Jaroszkiewicz, et al.
Biomedical Mass Spectrometry|June 1, 1982
Metabolism of 4-substituted-N-ethyl-N-methylanilines: chromatographic and mass spectrometric identification of N-oxidation metabolic products formed in vitroD A Cowan, L H Patterson, L A Damani, et al.
Biochemical Society Transactions|February 1, 1996
Rationalisation of the C-S lyase activity of aspartate amino transferaseP H Teesdale-Spittle, H J Adcock, L H Patterson, et al.
Biochemical Pharmacology|October 15, 1987
The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitroM A Graham, D R Newell, J Butler, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxidesP J Smith, N J Blunt, R Desnoyers, et al.
The Open Medical Informatics Journal|September 10, 2009
Analysis of Clinical Record Data for Anticoagulation Management within an EHR SystemT Austin, D Kalra, N C Lea, et al.
The Journal of Pharmacy and Pharmacology|April 1, 1986
In-vitro metabolism of lignocaine to its N-oxideL H Patterson, G Hall, B S Nijjar, et al.
International Journal of Radiation Oncology, Biology, Physics|December 9, 1998
Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrugS M Raleigh, E Wanogho, M D Burke, et al.
Anti-Cancer Drug Design|June 2, 2000
Antitumour prodrug development using cytochrome P450 (CYP) mediated activationL H Patterson, S R McKeown, T Robson, et al.
Pageof 7